Oculis Holding AG (OCS) Operating Expenses (2022 - 2026)
Oculis Holding AG (OCS) posted quarterly Operating Expenses of -$28.0 million for Q1 2026, down 24.32% year-over-year from -$37.0 million in Q1 2025, and down 6.4% quarter-over-quarter from -$26.3 million in Q4 2025.
Oculis Holding AG (OCS) Operating Expenses (2022 - 2026) Analysis & Trends
Oculis Holding AG's Operating Expenses history runs 5 years deep, the most recent figure standing at -$28.0 million for Q1 2026.
- In Q1 2026, Operating Expenses fell 24.32% year-over-year to -$28.0 million; the TTM figure through Mar 2026 stood at -$25.8 billion (down 21.24% YoY), while the FY2025 annual figure was -$100.0 million, down 19.0% from the prior year.
- Operating Expenses for Q1 2026 stood at -$28.0 million, down from -$26.3 million in the prior quarter.
- The five-year high for Operating Expenses was -$7.3 million in Q3 2022, with the low at -$25.7 billion in Q3 2025.
- The 5-year median for Operating Expenses is -$21.1 million (2024), against an average of -$2.9 billion.
- Peak annual rise in Operating Expenses reached 63.43% in 2024, while the deepest fall reached 141836.6% in 2024.
- Oculis Holding AG's Operating Expenses stood at -$11.8 million in 2022, then decreased by 18.6% to -$13.9 million in 2023, then slumped by 41.32% to -$19.7 million in 2024, then tumbled by 33.61% to -$26.3 million in 2025, then fell by 6.4% to -$28.0 million in 2026.
- Business Quant data shows OCS's Operating Expenses at -$28.0 million in Q1 2026, -$26.3 million in Q4 2025, and -$25.7 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Oculis Holding AG | 879.09 Mn | 590.21 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -28.01 Mn |
| Dec 31, 2025 | -26.33 Mn |
| Sep 30, 2025 | -25.68 Bn |
| Jun 30, 2025 | -25.40 Mn |
| Mar 31, 2025 | -22.53 Mn |
| Dec 31, 2024 | -19.71 Mn |
| Sep 30, 2024 | -21.18 Bn |
| Jun 30, 2024 | -25.13 Mn |
| Mar 31, 2024 | -17.82 Mn |
| Dec 31, 2023 | -13.94 Mn |
| Sep 30, 2023 | -14.92 Mn |
| Jun 30, 2023 | -12.23 Mn |
| Mar 31, 2023 | -48.71 Mn |
| Dec 31, 2022 | -11.76 Mn |
| Sep 30, 2022 | -7.33 Mn |
| Jun 30, 2022 | -9.84 Mn |